Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.
The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000. The share is part of SDAX, an index of the Deutsche Börse (German Stock Exchange) that includes Germany's most small-cap companies.
Revenues from immunotherapies increased by 38%
Cash & cash equivalents and time deposits (as of September, 30 2018)
Increase in research and development expenses to € 13.3 m for immunotherapies, as planned
The Annual General Meeting of Medigene shareholders for fiscal year 2017 was held in German language on Tuesday, 15 May 2018 at "Haus der Bayerischen Wirtschaft", Max-Joseph-Straße 5, 80333 Munich, Germany.
Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.
Julia Hofmann
Senior Director, Head of Public & Investor Relations
investor(at)medigene.com
public.relations(at)medigene.com
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20
Dr. Robert Mayer
Senior Manager Public & Investor Relations
investor(at)medigene.com
public.relations(at)medigene.com
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20